Intravenous UFH is useful in patients with NSTE- ACS undergoing PCI. (Level of Evidence: C) 3. Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH in patients with NSTE-ACS undergoing PCI.310,394 398 (Level of Evi- dence: B) 4. An additional dose of 0.3 mg/kg IV enoxaparin should be administered at the time of PCI to pa- tients with NSTE-ACS who have received fewer than 2 therapeutic subcutaneous doses (eg, 1 mg/kg SC) or received the last subcutaneous enoxaparin (Level of Evi- dence: B) 5. If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI be- cause of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time).26,313 315,404 (Level of Evidence: B) 6. In patients with NSTE-ACS, anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue such therapy. (Level of Evidence: C) Class IIa 1. In patients with NSTE-ACS undergoing PCI who are at high risk of bleeding, it is reasonable to use bivali- rudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist.310,396 (Level of Evidence: B) Class IIb 1. Performance of PCI with enoxaparin may be reason- able in patients treated with upstream subcutaneous enoxaparin for NSTE-ACS.26,309,399 402,405,406 (Level of Evidence: B) Class III: Harm 1. 